Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.42 |
| ▸ | CCNK | O75909 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950504 | 0.85 | CCNT1 (0.48) | PIM1PIM2CCNT1BRAF | |
| SCHEMBL9950178 | 0.83 | CCNT1 (0.44) | PIM1PIM2CCNT1CCNKCDK9 | |
| SCHEMBL9950120 | 0.81 | KDM4E (0.41) | CCNT1BRAF | |
| SCHEMBL9949639 | 0.81 | KDM4E (0.41) | CCNT1BRAF | |
| SCHEMBL10179191 | 0.79 | CCNT1 (0.48) | CCNT1CDK9 | |
| SCHEMBL9949605 | 0.79 | CCNT1 (0.57) | PIM1PIM2CCNT1CCNKCDK9 | |
| SCHEMBL9950884 | 0.77 | CCNT1 (0.40) | CCNT1CDK9IRAK4 | |
| SCHEMBL9950495 | 0.77 | CCNT1 (0.49) | CCNT1BRAF | |
| SCHEMBL9949992 | 0.77 | CCNT1 (0.50) | CCNT1BRAF | |
| SCHEMBL9950800 | 0.76 | SIRT6 (0.44) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | PIM1 491/4885PIM2 658/4885CCNT1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.